Base de dados : MEDLINE
Pesquisa : D12.776.828.868.915 [Categoria DeCS]
Referências encontradas : 142 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 15 ir para página                         

  1 / 142 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27579524
[Au] Autor:Arevalo-Villalobos JI; Rosales-Mendoza S; Zarazua S
[Ad] Endereço:a Laboratorio de Biofarmacéuticos Recombinantes, Facultad de Ciencias Químicas , Universidad Autónoma de San Luis Potosí , San Luis Potosí , México.
[Ti] Título:Immunotherapies for neurodegenerative diseases: current status and potential of plant-made biopharmaceuticals.
[So] Source:Expert Rev Vaccines;16(2):151-159, 2017 Feb.
[Is] ISSN:1744-8395
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:INTRODUCTION: Neurodegenerative diseases (NDs) have a serious impact on global health with no effective treatments available to date. Vaccination has been proposed as a therapeutic approach for NDs, and clinical evaluations of some candidates for Alzheimer's disease and multiple sclerosis are ongoing. Moreover, monoclonal antibodies for passive immunotherapy are under evaluation for Alzheimer's, synucleinopathies, and multiple sclerosis. Areas covered: With the consolidation of plant-based systems for the production and oral delivery of biopharmaceuticals, interesting perspectives arise in the fight against NDs. Based on analysis of the current biomedical literature, the role of plant-made biopharmaceuticals and the outlook on how this technology is leading to new therapeutic candidates and potential developments for NDs are presented in this review. Expert commentary: Substantial innovations in the following years are expected as a consequence of applying molecular pharming in the fight against NDs.
[Mh] Termos MeSH primário: Produtos Biológicos/administração & dosagem
Imunoterapia/métodos
Doenças Neurodegenerativas/terapia
Plantas Geneticamente Modificadas/metabolismo
Vacinas de Plantas Comestíveis/imunologia
[Mh] Termos MeSH secundário: Animais
Produtos Biológicos/isolamento & purificação
Produtos Biológicos/metabolismo
Descoberta de Drogas/tendências
Seres Humanos
Vacinas de Plantas Comestíveis/administração & dosagem
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Biological Products); 0 (Vaccines, Edible)
[Em] Mês de entrada:1707
[Cu] Atualização por classe:170731
[Lr] Data última revisão:
170731
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160901
[St] Status:MEDLINE
[do] DOI:10.1080/14760584.2016.1229602


  2 / 142 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:27754367
[Au] Autor:Joung YH; Park SH; Moon KB; Jeon JH; Cho HS; Kim HS
[Ad] Endereço:School of Biological Sciences & Technology, Chonnam National University, Gwangju 61186, Korea. yhjoung@chonnam.ac.kr.
[Ti] Título:The Last Ten Years of Advancements in Plant-Derived Recombinant Vaccines against Hepatitis B.
[So] Source:Int J Mol Sci;17(10), 2016 Oct 13.
[Is] ISSN:1422-0067
[Cp] País de publicação:Switzerland
[La] Idioma:eng
[Ab] Resumo:Disease prevention through vaccination is considered to be the greatest contribution to public health over the past century. Every year more than 100 million children are vaccinated with the standard World Health Organization (WHO)-recommended vaccines including hepatitis B (HepB). HepB is the most serious type of liver infection caused by the hepatitis B virus (HBV), however, it can be prevented by currently available recombinant vaccine, which has an excellent record of safety and effectiveness. To date, recombinant vaccines are produced in many systems of bacteria, yeast, insect, and mammalian and plant cells. Among these platforms, the use of plant cells has received considerable attention in terms of intrinsic safety, scalability, and appropriate modification of target proteins. Research groups worldwide have attempted to develop more efficacious plant-derived vaccines for over 30 diseases, most frequently HepB and influenza. More inspiring, approximately 12 plant-made antigens have already been tested in clinical trials, with successful outcomes. In this study, the latest information from the last 10 years on plant-derived antigens, especially hepatitis B surface antigen, approaches are reviewed and breakthroughs regarding the weak points are also discussed.
[Mh] Termos MeSH primário: Antígenos de Superfície da Hepatite B/imunologia
Vacinas contra Hepatite B/imunologia
Vacinas contra Hepatite B/uso terapêutico
Vírus da Hepatite B/imunologia
Hepatite B/prevenção & controle
Plantas Geneticamente Modificadas/genética
[Mh] Termos MeSH secundário: Animais
Biotecnologia/métodos
Expressão Gênica
Hepatite B/imunologia
Antígenos de Superfície da Hepatite B/genética
Vacinas contra Hepatite B/genética
Vírus da Hepatite B/genética
Seres Humanos
Vacinas de Plantas Comestíveis/genética
Vacinas de Plantas Comestíveis/imunologia
Vacinas de Plantas Comestíveis/uso terapêutico
Vacinas Sintéticas/genética
Vacinas Sintéticas/imunologia
Vacinas Sintéticas/uso terapêutico
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Hepatitis B Surface Antigens); 0 (Hepatitis B Vaccines); 0 (Vaccines, Edible); 0 (Vaccines, Synthetic)
[Em] Mês de entrada:1704
[Cu] Atualização por classe:170413
[Lr] Data última revisão:
170413
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161019
[St] Status:MEDLINE


  3 / 142 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:26708345
[Au] Autor:Rosales-Mendoza S; Angulo C; Meza B
[Ad] Endereço:Laboratorio de Biofarmacéuticos Recombinantes, Facultad de Ciencias Químicas, Universidad Autónoma de San Luis Potosí, Avenida Dr. Manuel Nava 6, SLP, 78210, México. Electronic address: rosales.s@fcq.uaslp.mx.
[Ti] Título:Food-Grade Organisms as Vaccine Biofactories and Oral Delivery Vehicles.
[So] Source:Trends Biotechnol;34(2):124-36, 2016 Feb.
[Is] ISSN:1879-3096
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:The use of food-grade organisms as recombinant vaccine expression hosts and delivery vehicles has been explored during the past 25 years, opening new avenues for vaccinology. Considering that oral immunization is a beneficial approach in terms of costs, patient comfort, and protection of mucosal tissues, the use of food-grade organisms can lead to highly advantageous vaccines in terms of costs, easy administration, and safety. The organisms currently used for this purpose are bacteria (Lactobacillus and Bacillus), yeasts, algae, plants, and insect species. Herein, a comparative and updated scenario on the production of oral vaccines in food-grade organisms is provided and placed in perspective. The status of clinical evaluations and the adoption of this technology by the industry are highlighted.
[Mh] Termos MeSH primário: Portadores de Fármacos
Microbiologia de Alimentos
Vacinas de Plantas Comestíveis/administração & dosagem
Vacinas de Plantas Comestíveis/isolamento & purificação
[Mh] Termos MeSH secundário: Administração Oral
Animais
Seres Humanos
Vacinas Sintéticas/administração & dosagem
Vacinas Sintéticas/isolamento & purificação
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T; REVIEW
[Nm] Nome de substância:
0 (Drug Carriers); 0 (Vaccines, Edible); 0 (Vaccines, Synthetic)
[Em] Mês de entrada:1610
[Cu] Atualização por classe:161230
[Lr] Data última revisão:
161230
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:151229
[St] Status:MEDLINE


  4 / 142 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:26519888
[Au] Autor:Shah S; Hayden CA; Fischer ME; Rao AG; Howard JA
[Ad] Endereço:Roy J. Carver Department of Biochemistry Biophysics and Molecular Biology, Iowa State University, Ames, IA 50011, USA.
[Ti] Título:Biochemical and biophysical characterization of maize-derived HBsAg for the development of an oral vaccine.
[So] Source:Arch Biochem Biophys;588:41-9, 2015 Dec 15.
[Is] ISSN:1096-0384
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Although a vaccine against hepatitis B virus (HBV) has been available since 1982, it is estimated that 600,000 people die every year due to HBV. An affordable oral vaccine could help alleviate the disease burden and to this end the hepatitis B surface antigen (HBsAg) was expressed in maize. Orally delivered maize material induced the strongest immune response in mice when lipid was extracted by CO2 supercritical fluid extraction (SFE), compared to full fat and hexane-extracted material. The present study provides a biochemical and biophysical basis for these immunological differences by comparing the active ingredient in the differently treated maize material. Purified maize-derived HBsAg underwent biophysical characterization by gel filtration, transmission electron microscopy (TEM), dynamic light scattering (DLS), UV-CD, and fluorescence. Gel filtration showed that HBsAg forms higher-order oligomers and TEM demonstrated virus-like particle (VLP) formation. The VLPs obtained from SFE were more regular in shape and size compared to hexane or full fat material. In addition, SFE-derived HBsAg showed the greatest extent of α-helical structure by far UV-CD spectrum. Fluorescence experiments also revealed differences in protein conformation. This work establishes SFE-treated maize material as a viable oral vaccine candidate and advances the development of the first oral subunit vaccine.
[Mh] Termos MeSH primário: Antígenos de Superfície da Hepatite B/química
Vacinas contra Hepatite B/química
Zea mays/genética
[Mh] Termos MeSH secundário: Administração Oral
Sequência de Aminoácidos
Animais
Cromatografia com Fluido Supercrítico
Antígenos de Superfície da Hepatite B/genética
Antígenos de Superfície da Hepatite B/isolamento & purificação
Vacinas contra Hepatite B/administração & dosagem
Vacinas contra Hepatite B/genética
Seres Humanos
Camundongos
Microscopia Eletrônica de Transmissão
Dados de Sequência Molecular
Fragmentos de Peptídeos/química
Fragmentos de Peptídeos/genética
Plantas Geneticamente Modificadas
Conformação Proteica
Estrutura Secundária de Proteína
Espectrometria de Fluorescência
Vacinas de Plantas Comestíveis/administração & dosagem
Vacinas de Plantas Comestíveis/química
Vacinas de Plantas Comestíveis/genética
Vacinas de Partículas Semelhantes a Vírus/administração & dosagem
Vacinas de Partículas Semelhantes a Vírus/química
Vacinas de Partículas Semelhantes a Vírus/genética
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, N.I.H., EXTRAMURAL
[Nm] Nome de substância:
0 (Hepatitis B Surface Antigens); 0 (Hepatitis B Vaccines); 0 (Peptide Fragments); 0 (Vaccines, Edible); 0 (Vaccines, Virus-Like Particle)
[Em] Mês de entrada:1604
[Cu] Atualização por classe:161215
[Lr] Data última revisão:
161215
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:151101
[St] Status:MEDLINE


  5 / 142 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:26254309
[Au] Autor:Takeyama N; Yuki Y; Tokuhara D; Oroku K; Mejima M; Kurokawa S; Kuroda M; Kodama T; Nagai S; Ueda S; Kiyono H
[Ad] Endereço:Research Department, Nippon Institute for Biological Science, Japan; Division of Mucosal Immunology, The Institute of Medical Science, The University of Tokyo, Japan.
[Ti] Título:Oral rice-based vaccine induces passive and active immunity against enterotoxigenic E. coli-mediated diarrhea in pigs.
[So] Source:Vaccine;33(39):5204-11, 2015 Sep 22.
[Is] ISSN:1873-2518
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:Enterotoxigenic Escherichia coli (ETEC) causes severe diarrhea in both neonatal and weaned pigs. Because the cholera toxin B subunit (CTB) has a high level of amino acid identity to the ETEC heat-labile toxin (LT) B-subunit (LTB), we selected MucoRice-CTB as a vaccine candidate against ETEC-induced pig diarrhea. When pregnant sows were orally immunized with MucoRice-CTB, increased amounts of antigen-specific IgG and IgA were produced in their sera. CTB-specific IgG was secreted in the colostrum and transferred passively to the sera of suckling piglets. IgA antibodies in the colostrum and milk remained high with a booster dose after farrowing. Additionally, when weaned minipigs were orally immunized with MucoRice-CTB, production of CTB-specific intestinal SIgA, as well as systemic IgG and IgA, was induced. To evaluate the cross-protective effect of MucoRice-CTB against ETEC diarrhea, intestinal loop assay with ETEC was conducted. The fluid volume accumulated in the loops of minipigs immunized with MucoRice-CTB was significantly lower than that in control minipigs, indicating that MucoRice-CTB-induced cross-reactive immunity could protect weaned pigs from diarrhea caused by ETEC. MucoRice-CTB could be a candidate oral vaccine for inducing both passive and active immunity to protect both suckling and weaned piglets from ETEC diarrhea.
[Mh] Termos MeSH primário: Diarreia/veterinária
Escherichia coli Enterotoxigênica/imunologia
Infecções por Escherichia coli/veterinária
Vacinas contra Escherichia coli/imunologia
Imunidade nas Mucosas
Oryza/genética
Doenças dos Suínos/prevenção & controle
[Mh] Termos MeSH secundário: Administração Oral
Animais
Anticorpos Antibacterianos/sangue
Colostro/imunologia
Diarreia/prevenção & controle
Escherichia coli Enterotoxigênica/genética
Infecções por Escherichia coli/prevenção & controle
Vacinas contra Escherichia coli/administração & dosagem
Vacinas contra Escherichia coli/genética
Feminino
Imunização Passiva
Imunoglobulina A/sangue
Imunoglobulina G/sangue
Leite/imunologia
Gravidez
Soro/imunologia
Suínos
Vacinação
Vacinas de Plantas Comestíveis/administração & dosagem
Vacinas de Plantas Comestíveis/genética
Vacinas de Plantas Comestíveis/imunologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Antibodies, Bacterial); 0 (Escherichia coli Vaccines); 0 (Immunoglobulin A); 0 (Immunoglobulin G); 0 (Vaccines, Edible)
[Em] Mês de entrada:1606
[Cu] Atualização por classe:150921
[Lr] Data última revisão:
150921
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:150809
[St] Status:MEDLINE


  6 / 142 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:26232545
[Au] Autor:Sarker AR; Islam Z; Khan IA; Saha A; Chowdhury F; Khan AI; Cravioto A; Clemens JD; Qadri F; Khan JA
[Ad] Endereço:International Centre for Diarrheal Disease Research, Bangladesh (icddr,b), Dhaka, Bangladesh. Electronic address: arazzaque@icddrb.org.
[Ti] Título:Estimating the cost of cholera-vaccine delivery from the societal point of view: A case of introduction of cholera vaccine in Bangladesh.
[So] Source:Vaccine;33(38):4916-21, 2015 Sep 11.
[Is] ISSN:1873-2518
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:Cholera is a major global public health problem that causes both epidemic and endemic disease. The World Health Organization recommends oral cholera vaccines as a public health tool in addition to traditional prevention practices and treatments in both epidemic and endemic settings. In many developing countries like Bangladesh, the major issue concerns the affordability of this vaccine. In February 2011, a feasibility study entitled, "Introduction of Cholera Vaccine in Bangladesh (ICVB)", was conducted for a vaccination campaign using inactivated whole-cell cholera vaccine (Shanchol) in a high risk area of Mirpur, Dhaka. Empirical data obtained from this trial was used to determine the vaccination cost for a fully immunized person from the societal perspective. A total of 123,661 people were fully vaccinated receiving two doses of the vaccine, while 18,178 people received one dose of the same vaccine. The total cost for vaccine delivery was US$ 492,238 giving a total vaccination cost per fully-vaccinated individual of US$ 3.98. The purchase cost of the vaccine accounted for 58% of the overall cost of vaccination. Attempts to reduce the per-dose cost of the vaccine are likely to have a large impact on the cost of similar vaccination campaigns in the future.
[Mh] Termos MeSH primário: Vacinas contra Cólera/administração & dosagem
Vacinas contra Cólera/economia
Cólera/prevenção & controle
Custos de Cuidados de Saúde
Vacinação/economia
[Mh] Termos MeSH secundário: Administração Oral
Adolescente
Adulto
Idoso
Idoso de 80 Anos ou mais
Bangladesh/epidemiologia
Criança
Pré-Escolar
Cólera/epidemiologia
Estudos de Viabilidade
Feminino
Seres Humanos
Lactente
Masculino
Meia-Idade
Vacinas de Plantas Comestíveis/administração & dosagem
Vacinas de Plantas Comestíveis/economia
Vacinas de Produtos Inativados/administração & dosagem
Vacinas de Produtos Inativados/economia
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Cholera Vaccines); 0 (Vaccines, Edible); 0 (Vaccines, Inactivated)
[Em] Mês de entrada:1606
[Cu] Atualização por classe:150908
[Lr] Data última revisão:
150908
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:150802
[St] Status:MEDLINE


  7 / 142 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:26073010
[Au] Autor:Salazar-González JA; Angulo C; Rosales-Mendoza S
[Ad] Endereço:Laboratorio de Biofarmacéuticos Recombinantes, Facultad de Ciencias Químicas, Universidad Autónoma de San Luis Potosí, Av. Dr. Manuel Nava 6, San Luis Potosí 78210, SLP, Mexico.
[Ti] Título:Chikungunya virus vaccines: Current strategies and prospects for developing plant-made vaccines.
[So] Source:Vaccine;33(31):3650-8, 2015 Jul 17.
[Is] ISSN:1873-2518
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:Chikungunya virus is an emerging pathogen initially found in East Africa and currently spread into the Indian Ocean Islands, many regions of South East Asia, and in the Americas. No licensed vaccines against this eminent pathogen are available and thus intensive research in this field is a priority. This review presents the current scenario on the developments of Chikungunya virus vaccines and identifies the use of genetic engineered plants to develop attractive vaccines. The possible avenues to develop plant-made vaccines with distinct antigenic designs and expression modalities are identified and discussed considering current trends in the field.
[Mh] Termos MeSH primário: Febre de Chikungunya/prevenção & controle
Vírus Chikungunya/imunologia
Vacinas Virais/imunologia
[Mh] Termos MeSH secundário: África/epidemiologia
Américas/epidemiologia
Ásia Sudeste/epidemiologia
Febre de Chikungunya/epidemiologia
Descoberta de Drogas/tendências
Seres Humanos
Ilhas do Oceano Índico/epidemiologia
Plantas Geneticamente Modificadas
Vacinas de Plantas Comestíveis/imunologia
Vacinas de Plantas Comestíveis/isolamento & purificação
Vacinas Sintéticas/imunologia
Vacinas Sintéticas/isolamento & purificação
Vacinas de Partículas Semelhantes a Vírus/imunologia
Vacinas de Partículas Semelhantes a Vírus/isolamento & purificação
Vacinas Virais/isolamento & purificação
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T; REVIEW
[Nm] Nome de substância:
0 (Vaccines, Edible); 0 (Vaccines, Synthetic); 0 (Vaccines, Virus-Like Particle); 0 (Viral Vaccines)
[Em] Mês de entrada:1603
[Cu] Atualização por classe:150704
[Lr] Data última revisão:
150704
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:150616
[St] Status:MEDLINE


  8 / 142 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:25882610
[Au] Autor:Rosales-Mendoza S; Govea-Alonso DO
[Ad] Endereço:Laboratorio de Biofarmacéuticos Recombinantes, Facultad de Ciencias Químicas, Universidad Autónoma de San Luis Potosí, Av. Dr. Manuel Nava 6, SLP, 78210, México, USA.
[Ti] Título:The potential of plants for the production and delivery of human papillomavirus vaccines.
[So] Source:Expert Rev Vaccines;14(7):1031-41, 2015 Jul.
[Is] ISSN:1744-8395
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:The available vaccines against human papillomavirus have some limitations such as low coverage due to their high cost, reduced immune coverage and the lack of therapeutic effects. Recombinant vaccines produced in plants (genetically engineered using stable or transient expression systems) offer the possibility to obtain low cost, efficacious and easy to administer vaccines. The status on the development of plant-based vaccines against human papillomavirus is analyzed and placed in perspective in this review. Some candidates have been characterized at a preclinical level with interesting outcomes. However, there is a need to perform the immunological characterization of several vaccine prototypes, especially through the oral administration route, as well as develop new candidates based on new chimeric designs intended to provide broader immunoprotection and therapeutic activity.
[Mh] Termos MeSH primário: Infecções por Papillomavirus/prevenção & controle
Vacinas contra Papillomavirus/administração & dosagem
Vacinas contra Papillomavirus/isolamento & purificação
Plantas Geneticamente Modificadas
Tecnologia Farmacêutica/métodos
[Mh] Termos MeSH secundário: Descoberta de Drogas/tendências
Seres Humanos
Infecções por Papillomavirus/imunologia
Vacinas contra Papillomavirus/genética
Vacinas contra Papillomavirus/imunologia
Vacinas de Plantas Comestíveis/administração & dosagem
Vacinas de Plantas Comestíveis/genética
Vacinas de Plantas Comestíveis/imunologia
Vacinas de Plantas Comestíveis/isolamento & purificação
Vacinas Sintéticas/administração & dosagem
Vacinas Sintéticas/genética
Vacinas Sintéticas/imunologia
Vacinas Sintéticas/isolamento & purificação
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T; REVIEW
[Nm] Nome de substância:
0 (Papillomavirus Vaccines); 0 (Vaccines, Edible); 0 (Vaccines, Synthetic)
[Em] Mês de entrada:1602
[Cu] Atualização por classe:150618
[Lr] Data última revisão:
150618
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:150418
[St] Status:MEDLINE
[do] DOI:10.1586/14760584.2015.1037744


  9 / 142 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:25840367
[Au] Autor:Rukavtsova EB; Rudenko NV; Puchko EN; Zakharchenko NS; Buryanov YI
[Ad] Endereço:Branch of Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Science Avenue, 6, Pushchino, Moscow Region 142290, Russia. Electronic address: rukavtsova62@gmail.com.
[Ti] Título:Study of the immunogenicity of hepatitis B surface antigen synthesized in transgenic potato plants with increased biosafety.
[So] Source:J Biotechnol;203:84-8, 2015 Jun 10.
[Is] ISSN:1873-4863
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:Oral immunogenicity of the hepatitis B surface antigen (HBsAg) synthesized in the tubers of marker-free potato plants has been demonstrated. Experiments were performed in the two groups of outbred NMRI mice. At the beginning of investigations, the mice of experimental group were fed the tubers of transgenic potato synthesizing the HBsAg three times. The mice of control group were fed nontransgenic potato. Intraperitoneal injection of the commercial vaccine against hepatitis B (0.5µg/mouse) was made on day 71 of the experiment. Enzyme-linked immunoassay (ELISA) of the serum of immunized animals showed an increase in the level of HBsAg antibodies significantly above the protective value, which was maintained for 1 year after the immunization. In 1 year, the experimental group of mice underwent additional oral immunization with HBsAg-containing potato tubers. As a result, the level of antibodies against the HBsAg increased and remained at a high protective level for several months. The findings show the possibility of using transgenic plants as a substance for obtaining a safe edible vaccine against hepatitis B.
[Mh] Termos MeSH primário: Antígenos de Superfície da Hepatite B/biossíntese
Antígenos de Superfície da Hepatite B/imunologia
Vacinas contra Hepatite B/administração & dosagem
Plantas Geneticamente Modificadas/metabolismo
Solanum tuberosum/metabolismo
[Mh] Termos MeSH secundário: Animais
Camundongos
Tubérculos
Solanum tuberosum/genética
Vacinas de Plantas Comestíveis
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Hepatitis B Surface Antigens); 0 (Hepatitis B Vaccines); 0 (Vaccines, Edible)
[Em] Mês de entrada:1602
[Cu] Atualização por classe:150502
[Lr] Data última revisão:
150502
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:150404
[St] Status:MEDLINE


  10 / 142 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
[PMID]:25811472
[Au] Autor:Lucka M; Kowalczyk T; Szemraj J; Sakowicz T
[Ad] Endereço:Studentka V roku kier. Biotechnologia UL. Katedra Genetyki Ogólnej, Biologii Molekularnej i Biotechnologii Roslin, Wydzial Biologii i Ochrony Srodowiska, Uniwersytet Lódzki.
[Ti] Título:[Plants as an alternative source of therapeutic proteins].
[Ti] Título:Rosliny jako alternatywne zródlo bialek terapeutycznych..
[So] Source:Postepy Hig Med Dosw (Online);69:362-73, 2015 Mar 22.
[Is] ISSN:1732-2693
[Cp] País de publicação:Poland
[La] Idioma:pol
[Ab] Resumo:In recent years, there has been an increased interest of researchers in developing efficient plant heterologous expression systems of proteins for a wide range of applications. It represents an alternative to the traditional strategy utilizing bacterial, yeast, insect or mammalian cells. New techniques of identification and characterization and effective methods of plant genetic transformation allow the range of recombinant protein products to be expanded. Great expectations are associated with the use of plants as bioreactors for the production of specific proteins of therapeutic interest. This strategy offers a number of advantages, the most important being: the possibility of a significant reduction in production costs, the safety of the products obtained and full eukaryotic post-translational modifications of proteins. A group of proteins of special interest is pharmaceuticals, and a number of successful experiments have confirmed the possibility of obtaining heterogeneous proteins with therapeutic potential: monoclonal antibodies, vaccine antigens, and a variety of cytokines. This work is focused on selected recombinant proteins belonging to those groups expression of which was achieved in plant cells. These proteins may be used in the future for therapy or prevention of viral, bacterial or cancer diseases.
[Mh] Termos MeSH primário: Anticorpos Monoclonais/biossíntese
Antígenos/biossíntese
Proteínas de Plantas/biossíntese
Plantas Geneticamente Modificadas/metabolismo
Engenharia de Proteínas/métodos
Proteínas Recombinantes/biossíntese
Vacinas de Plantas Comestíveis/biossíntese
[Mh] Termos MeSH secundário: Animais
Processamento de Proteína Pós-Traducional
[Pt] Tipo de publicação:ENGLISH ABSTRACT; JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Antibodies, Monoclonal); 0 (Antigens); 0 (Plant Proteins); 0 (Recombinant Proteins); 0 (Vaccines, Edible)
[Em] Mês de entrada:1508
[Cu] Atualização por classe:161021
[Lr] Data última revisão:
161021
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:150327
[St] Status:MEDLINE



página 1 de 15 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde